Band cell origin of in vivo emerging neutrophil-DC hybrids. (A-B) Gr-1^high/CD48⁻ band cells purified from C57BL/6 (CD45.2) mice were intravenously injected into B6 SJL (CD45.1) recipient mice that had received thioglycollate treatment 6 hours earlier. The PECs harvested on day 3 (A) or at the indicated time points (B) were examined for CD11c and MHC II expression profiles and the percentages (means ± SD, n = 3) of CD11c⁺ cells and MHC II⁺ cells within the CD45.2⁺/CD45.1⁻ gated population. (C-D) Gr-1^high/CD48⁻ band cells purified from CD11c promoter-driven DTR-EGFP TG mice (C, red in upper panels), I-Aβ-EGFP knock-in mice (C, red in lower panels), or WT mice (C, blue in all panels) were examined for GFP fluorescence signals before and 3 days after adoptive transfer into B6 SJL recipient mice as in (A). Data shown are GFP expression profiles and the percentages (means ± SD, n = 3) of GFP⁺ cells within the CD45.2⁺/CD45.1⁻ gated population. (E-F) Gr-1^high/CD48⁻ band cells purified from C57BL/6 (CD45.2) mice were adoptively transferred to B6 SJL recipients that had received intraperitoneal injection of thioglycollate (middle panels) or E. coli 6 hours earlier (right panels). The starting band cell preparations (left panels) and the CD45.2⁺/CD45.1⁻ fractions FACS purified from the peritonitis lesions were examined for morphology. (E) Data shown are representative images (bars indicate 20 μm). (F) The percent of cells showing the indicated nuclear shapes were determined by analyzing >500 cells per sample under the microscopy. All data are representative of at least 2 independent 2experiments.